Scotiabank analyst Louise Chen initiated coverage of Cogent Biosciences (COGT) with an Outperform rating and $17 price target Positive readouts from three registrational studies this year could significantly increase confidence in Cogent’s potentially BIC KITis and drive the stock higher, the firm says. Positive data from Part 1 of these studies help de-risk the upcoming readouts. These assets have U.S. peak sales potential of $3B, but Scotiabank does not believe this is reflected in Cogent’s valuation yet.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COGT:
- Buy Rating for Cogent Biosciences Backed by Promising Clinical Trial Results and Market Potential
- Cogent Biosciences Reports 2024 Financial Results and Clinical Progress
- Cogent Biosciences announces expanded results from OLE portion of SUMMIT trial
- Cogent Biosciences price target lowered to $8 from $10 at Baird
- Cogent Biosciences: Promising Pipeline and Financial Stability Drive Buy Rating